G
Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Our proprietary nicotinamide (NAM) technology expands the number of cells while maintaining their intrinsic properties to create potentially curative cell therapy products and candidates for patients with cancer. Our stem cell transplant therapy was approved by the US FDA in April 2023. Clinical study of our NK cell therapy candidate GDA-201 is ongoing.
Investor insights
Funding rounds participated in
$25M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
1998
Funding rounds raised
Total raised
$25M
from 1 investors over 1 rounds
G
Gamida Cell Ltd. raised $25M on October 28, 2022
Investors: Highbridge Capital Management